logo
Farmers deploy next-gen solution to protect world's most expensive spice: 'Amazing innovation'

Farmers deploy next-gen solution to protect world's most expensive spice: 'Amazing innovation'

Yahoo23-02-2025

Scientists are moving quickly to protect India's production of an iconic and coveted spice, saffron, from rising threats like record-setting temperatures, urbanization, and unpredictable rainfall.
Reuters reported on the impact on the Kashmir region, which accounts for 90% of the nation's production. Saffron is the world's most valuable spice that can command up to 325,000 rupees ($3,800 USD) a kilogram (2.2 pounds). Cultivating it is labor-intensive and includes picking the saffron by hand off of the bright purple flowers of crocus plants.
India is second in the world to Iran in saffron production, with much of it in the farms of the Kashmir town of Pampore. Unfortunately, that output is lagging. In the 2010-11 financial year, the nation produced 8.8 tons of the spice. By 2023-24, the federal government revealed that number had been cut by more than a third to 2.8 tons.
To address the issue, farming crocus plants indoors is a remedy to the outdoors' ever-changing and frequently inhospitable climate. One of the scientists involved, Dr. Bashir Ilahi, told Reuters that cultivating saffron indoors in tubes with essential nutrients and appropriate levels of moisture offers many advantages.
"Growing saffron in a controlled environment demonstrates temperature resistance and significantly reduces the risk of crop failure," Ilahi noted. While many local farmers relish in the old-school process of growing it outdoors, Ilahi and others have found takers after giving demonstrations on indoor farming.
Abdul Majeed, president of Kashmir's Saffron Growers Association, called the development an "amazing innovation." Majeed himself is an indoor grower.
The scientists' proactive solution using indoor farming is part of many attempts to leverage the new technology. A startup, Plenty, is an exciting solution that can help cut down on pesticide use while using less land and water than conventional outdoor plots. Scientists have even gone so far as to explore indoor farming that includes growing crops in the dark.
While those examples of indoor farming are intended to minimize the use of land, water, and pesticides, India's use of it joins other attempts to get creative in fighting climate threats.
There's a global effort to engineer more resilient crops that can withstand the increase in threats like floods, extreme heat, and droughts. To get there, scientists are trying to learn new insights about how plants protect themselves against threats. It's a big challenge, but all of these innovations can help protect against food insecurity while helping to make agriculture more efficient and viable in the long term.
Do you think we still have a lot to learn from ancient cultures?
Definitely
Only on certain topics
I'm not sure
No — not really
Click your choice to see results and speak your mind.
As long as the world keeps getting hotter, extreme weather events and more challenging conditions for agriculture look to be a certain reality. Some saffron growers in India are urging the country to do even more to protect farmers against the rising risks to the crop.
"The government should promote indoor saffron cultivation on a much larger scale as climate change is affecting the entire world, and Kashmir is no exception," saffron grower Manzoor Ahmad Mir related to Reuters.
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Russia says it tests new laser defences against drones
Russia says it tests new laser defences against drones

Yahoo

time13 hours ago

  • Yahoo

Russia says it tests new laser defences against drones

MOSCOW (Reuters) -Russia said on Friday it had conducted large-scale tests of new laser-based systems to defend against drones. A government statement described the new technology as "promising" and said it had been tested against various types of drone in different weather conditions. It said the anti-drone lasers would become part of a "universal air defence system" that President Vladimir Putin said this week Russia needed to build. "The test results will be used to refine existing models and create systems capable of providing reliable protection against modern air attack weapons. Conducting tests allows us to move on to serial production and upscaling," the statement said. An accompanying video showed charred debris from a destroyed drone. Both sides have deployed drones on a huge scale in the Russia-Ukraine war, using them to spot and hit targets not only on the battlefield but way beyond the front lines. Ukrainian drones have frequently struck sites deep inside Russia such as oil depots, refineries and airfields, highlighting the need for Moscow to boost its defences. Earlier this month, Ukrainian drones smuggled close to air bases in trucks inflicted serious damage to Russia's long-range bomber fleet.

Russia says it tests new laser defences against drones
Russia says it tests new laser defences against drones

Yahoo

time14 hours ago

  • Yahoo

Russia says it tests new laser defences against drones

MOSCOW (Reuters) -Russia said on Friday it had conducted large-scale tests of new laser-based systems to defend against drones. A government statement described the new technology as "promising" and said it had been tested against various types of drone in different weather conditions. It said the anti-drone lasers would become part of a "universal air defence system" that President Vladimir Putin said this week Russia needed to build. "The test results will be used to refine existing models and create systems capable of providing reliable protection against modern air attack weapons. Conducting tests allows us to move on to serial production and upscaling," the statement said. An accompanying video showed charred debris from a destroyed drone. Both sides have deployed drones on a huge scale in the Russia-Ukraine war, using them to spot and hit targets not only on the battlefield but way beyond the front lines. Ukrainian drones have frequently struck sites deep inside Russia such as oil depots, refineries and airfields, highlighting the need for Moscow to boost its defences. Earlier this month, Ukrainian drones smuggled close to air bases in trucks inflicted serious damage to Russia's long-range bomber fleet.

Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Report: Multispecific Antibodies Market to Surpass USD 50 Billion by 2030
Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Report: Multispecific Antibodies Market to Surpass USD 50 Billion by 2030

Yahoo

time14 hours ago

  • Yahoo

Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Report: Multispecific Antibodies Market to Surpass USD 50 Billion by 2030

Explore the booming Global Multispecific Antibodies Market set to surpass USD 50 billion by 2030. Key highlights include sales insights, approved drugs, and clinical trials from over 700 antibodies. Significant contributors like Roche and rising players ensure ongoing innovation in this dynamic biopharma sector. Dublin, June 13, 2025 (GLOBE NEWSWIRE) -- The "Global Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Insight 2030" report has been added to Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Insight 2030 Report Highlights: Global Multispecific Antibodies Market Opportunity By 2030: > USD 50 Billion Global Multispecific Antibodies Market Sales In 2024: > USD 12 Billion Number Of Approved Multispecific Antibodies: 18 Global & Regional Trends Insight Approved Antibodies Global, Regional, Annual & Quarterly Sales Insight Approved Antibodies Dosage & Pricing Insight Comprehensive Insight On All Antibodies In Clinical Trials By Company, Country, Indication & Phase Number Of Multispecific Antibodies: In Clinical Trials: > 700 Multispecific antibodies market globally has been one of the most energetic and fast growing sectors in the biopharmaceutical business as a result of therapeutic breakthroughs and growing acceptance of their ability to treat complicated pathologies by targeting multiple pathways simultaneously. As of May 2025, 18 multispecific antibodies have gained regulatory approval globally, all of which are bispecific constructs, a monumental milestone in the history of targeted therapeutics. This expanding portfolio boasts trailblazing drugs like Blincyto, the first bispecific antibody to gain approval, and Hemlibra, which was the first bispecific antibody to be approved for a non-cancer indication. The latest entrant to this therapeutic pipeline is Regeneron's Lynozyfic, which received marketing approval in April 2025 for the treatment of multiple myeloma, with evidence of ongoing momentum in the segment. The range of approved multispecific antibodies mirrors the flexibility of this therapeutic modality across various disease indications and patient bases. Rybrevant is another key breakthrough as the first bispecific antibody for a solid tumor, whereas China based Akeso's Cadonilimab is especially noteworthy for being solely approved bispecific antibody intended to target two immune checkpoints at once and becoming the first China developed bispecific antibody to gain regulatory approval. This regional variation in development emphasizes the world nature of innovation in this sector, with input from both mature pharmaceutical markets and developing biotechnology centers. The regulatory environment is still changing at a rapid pace, with further approvals expected in the near future. The FDA is also evaluating marketing applications for Odronextamab and Linvoseltamab, both of which have already received approval in the EU for follicular lymphoma and diffuse large B-cell lymphoma, and multiple myeloma, respectively. Such transatlantic regulatory advancements reflect the growing acceptability and trust in multispecific antibody technologies by global regulatory bodies. Market performance has been extremely strong, with global multispecific antibodies market sales in 2024 amounting to over US$ 12.6 Billion, followed by first quarter 2025 sales of over US$ 3.46 Billion. The US is the largest contributor to these sales, highlighting the maturity and acceptance of the market in this prime geography. Roche's mature products, Hemlibra and Vabysmo, lead the market share, with over half of total sales, emphasizing the value of first mover benefit and effective market entry strategies in this competitive market. The pipeline for development is an even more daunting picture, with more than 900 multispecific antibodies already in various stages of development. Oncology is leading this pipeline, both due to the traditional priority of multispecific antibody development and due to the large unmet medical needs in cancer treatment. However, pipeline diversity is not confined to oncology alone with promising candidates being identified in autoimmune and inflammatory diseases and neurological disorders as well, indicating an expanding therapeutic horizon that has the potential to dramatically expand market opportunities. Major industry players behind this innovation are well established pharma giants like Amgen, AstraZeneca, Genentech, and Regeneron, as well as new biotech firms like ABL Bio, Harbour BioMed, Innovent Biologics, Merus, and Zymeworks. This combination of well established and new players provides a vibrant competitive landscape that ensures ongoing innovation and technological progress. Strategic alliances continue to influence the development of the market, such as in the April 2025 alliance of Boehringer Ingelheim and Cue Biopharma for the development of CUE-501, a bispecific candidate that attacks pathogenic B cells via virus-specific memory T cells. The alliance, involving a US$ 12 Million upfront payment and possible milestone payments of up to US$ 345 Million, illustrates the high financial investment that companies are undertaking to drive multispecific antibody technologies, specifically in autoimmune indications where existing treatments are still inadequate. Regulatory encouragement of innovation continues to be robust, with the FDA's April 2025 fast track designation of ISB 2001, an Ichnos Glenmark Innovation investigational trispecific T-cell engager for relapsed or refractory multiple myeloma, reflecting ongoing regulatory enthusiasm for moving multispecific antibody technologies forward that treat important unmet medical needs. As a result of these ongoing innovations, the global multispecific antibody market is expected to grow rapidly and is on track to become one of the most important segments within the pharmaceutical industry. Key Topics Covered: 1. Introduction to Next Generation Multispecific Antibodies 2. Next Generation Multispecific Antibody Current Clinical Development & Future Commercialization Outlook2.1 Current Market Overview2.2 Future Commercialization Opportunity2.3 Collaborations, License Agreements, Investments & Acquisitions2.4 Next Generation Multispecific Antibody Proprietary Technologies By Company 3. Next Generation Multispecific Antibody Clinical Trends by Indication3.1 Cancer3.2 Hematological Disorders3.3 Microbial Infections3.4 Autoimmune & Inflammatory Disorders3.5 Ocular Diseases 4. Next Generation Multispecific Antibody Clinical Development & Market Trends by Region4.1 US4.2 EU4.3 China4.4 UK4.5 Japan4.6 Australia4.7 South Korea4.8 Canada 5. Approved Multispecific Antibodies - Clinical Overview, Pricing & Dosage Insight5.1 Overview5.2 Clinical Overview, Pricing & Dosage Insight 6. Approved Multispecific Antibodies - Sales Insight (2020 - Q1'2025) 7. Global Multispecific Antibodies Clinical Trials Overview 8. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase8.1 Research8.2 Preclinical8.3 Phase-I8.4 Phase-I/II8.5 Phase-II8.6 Phase-II/III8.7 Phase-III8.8 Preregistration8.9 Registered 9. Marketed Bispecific Antibodies Clinical Insight By Company, Country & Indication 10. Global Trispecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase10.1 Research10.2 Preclinical10.3 Phase I10.4 Phase I/II10.5 Phase II/III 11. Tetraspecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase11.1 Preclinical11.2 Phase I11.3 Phase I/II11.4 Phase II 12. Competitive Landscape AbbVie ABL Bio Abzyme Therapeutics Affimed Therapeutics Akeso Biopharma Alligator Bioscience Amgen Antibody Therapeutics APITBIO Astellas Pharma AstraZeneca Aptevo Therapeutics BioAtla Biocytogen Pharmaceuticals Biosion EpimAb Biotherapeutics FutureGen Biopharmaceutical Genentech Genmab Genor Biopharma Gensun Biopharma Harbour BioMed IGM Biosciences I-MAB Biopharma ImmuneOnco Biopharma ImmunoPrecise Antibodies Innate Pharma Innovent Biologics Invenra Johnson & Johnson Kenjockety Biotechnology LaNova Medicines Limited Light Chain Bioscience Linton Pharm Lyvgen Biopharma MacroGenics Merck Merus ModeX Therapeutics (OPKO Health) Molecular Partners NovaRock Biotherapeutics Numab OPKO Health Pfizer Regeneron Pharmaceuticals Revitope Roche Sanofi Sichuan Baili Pharmaceutical SystImmune Virtuoso Therapeutics Xencor Y-Biologics Zhejiang Shimai Pharmaceutical Zymeworks For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store